In fact, CD155 expression on melanomas has also shown to be associated with a poorer response of metastatic melanoma patients to anti-PD-1 monotherapy and combination anti-PD-1 and CTLA-4 [40]. This evidence concerns the gene CTLA4 and metastatic melanoma.